ARTICLE | Product Development
Pfizer, BioNTech first to test COVID-19 vaccine candidate on two continents
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
May 5, 2020 9:50 PM UTC
Updated on May 6, 2020 at 4:40 PM UTC
The announcement Tuesday that healthy volunteers in the U.S. have received a candidate RNA vaccine from Pfizer and BioNTech marks the first COVID-19 vaccine to enter clinical testing on two continents.
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) completed the first dosing cohort of a Phase I/II trial of their BNT162 vaccine candidate in Germany on April 29. ...